Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen Vaccine, Tislelizumab, and Chemotherapy in Resected Pancreatic Cancer
NCT06344156Phase 1Recruiting
- Sponsor
- Sichuan University
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of NeoVax in pancreatic ductal adenocarcinoma (PDAC), sponsored by Sichuan University. Primary endpoint: Recurrence-Free Survival at 18 months. Started Apr 2024; status: recruiting.
02
Drugs
NeoVax
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06344156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06344156.